MétaCan
Menu
Back to cohort
Record W4365505364 · doi:10.1111/all.15743

Assessment of dupilumab in children with moderate‐to‐severe type 2 asthma with or without evidence of allergic asthma

2023· article· en· W4365505364 on OpenAlexaff
Nikolaos G. Papadopoulos, Stanley J. Szefler, Leonard B. Bacharier, Jorge Máspero, Christian Domingo, Alessandro Fiocchi, Jason K. Lee, Nadia Daizadeh, David J. Lederer, Megan Hardin, Rebecca Gall, Michel Djandji, Shahid Siddiqui, Juby A. Jacob‐Nara, Yamo Deniz, Paul J. Rowe

Bibliographic record

VenueAllergy · 2023
Typearticle
Languageen
FieldMedicine
TopicAsthma and respiratory diseases
Canadian institutionsOttawa Allergy Research Corporation
FundersSanofi
KeywordsDupilumabAsthmaMedicineAllergic asthmaImmunologyAllergyDermatologyPediatrics

Abstract

fetched live from OpenAlex

Abstract Background Cytokines, such as interleukins (IL)‐4/5/13, play a key role in multiple type 2 inflammatory diseases, including allergic asthma. Dupilumab, a human monoclonal antibody, blocks the shared receptor component for IL‐4/IL‐13, inhibiting signaling. In this post hoc analysis of VOYAGE (NCT02948959), dupilumab efficacy was evaluated in patients aged 6–11 years with type 2 asthma with or without evidence of allergic asthma (baseline serum total IgE ≥30 IU/mL and ≥1 perennial aeroallergen‐specific IgE ≥0.35kU/L). Methods Annualized severe exacerbation rates (AER) and changes in pre‐bronchodilator (Pre‐BD) forced expiratory volume in one second (FEV 1 ), percent‐predicted pre‐BD FEV 1 (ppFEV 1 ), and Asthma Control Score (ACQ)‐7 were assessed during the treatment period. Results 350 children (261 with and 89 without evidence of allergic asthma) were included. Dupilumab versus placebo significantly reduced AER in patients with (0.24 vs. 0.62, relative risk reduction [RRR]: 62% [95% CI, 39–76], P < .0001) and without (0.39 vs. 0.80, RRR: 51% [95% CI, 0–76], P < .05) evidence of allergic asthma. Significant improvements in ppFEV 1 , pre‐bronchodilator FEV 1 , and ACQ‐7 scores were observed in dupilumab versus placebo throughout the treatment period in patients with evidence of allergic asthma. In patients without evidence of allergic asthma, numerical improvements in pre‐bronchodilator FEV 1 and asthma control were observed by Week 52. Conclusion Dupilumab versus placebo reduced asthma exacerbations in children with type 2 asthma irrespective of evidence of allergic asthma; similar trends were observed in changes in lung function. Significant improvement in asthma control was observed in patients with evidence of allergic asthma, but not in those without.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.037
Threshold uncertainty score0.584

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.023
GPT teacher head0.313
Teacher spread0.290 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations25
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueAllergySame topicAsthma and respiratory diseasesFrench-language works237,207